Although the mouse xenograft model can also secure patient-derived cancer cells, the response to ICIs may vary depending on the host organism, as shown through the discrepancy in the results of clinical trials of MEK inhibitors25 with PD-L1 treatment26. Here, MAP2K7 is linked to cancer.